Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus DERMABET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus DERMABET.
CORTAN vs DERMABET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid